350 rub
Journal Technologies of Living Systems №4 for 2012 г.
Article in number:
Application combined hypolipidemic management for correction cardiovascular risk and lewel glycemia in patients with metabolic syndrom
Keywords: metabolic syndrome diabetes mellitus type 2 arterial hypertension ischemic heart disease Ateroblock Aktalipid associations between blood viscosity glycemia and cardiovascular risk
Authors:
A.F. Apukhtin, L.I. Inina
Abstract:
The results of studying the characteristics of the dynamics of cardiovascular risk in patients with type 2 diabetes with concomitant cardiovascular disease in the separate and combined use of statins and ω-3 polyunsaturated fatty acids in relation to glycemic and blood clotting. A total of 40 patients with type 2 diabetes in the compensation stage and sub-compensation of carbohydrate metabolism. The average patient age was 63,2 ± 10,6 years. Following the randomized into two groups, patients in the first (primary) group (n = 20) in addition to basic therapy was prescribed «Aktalipid» daily dose of 20 mg and the drug «Ateroblok» at dose of 2 capsules (1 g) per day during the meal in the morning and evening. Patients of the 2nd (control) group was prescribed «Aktalipid» in the same daily dosage of the drug without "Ateroblok." The patients received basic therapy hypertension and coronary heart disease: enalapril, amlodipine, metoprolol, aspirin, nitrates, if necessary. As the glucose lowering therapies were used oral hypoglycemic agent sulfonylurea derivatives (glibenclamide) and / or a biguanide (metformin). The study lasted 12 weeks. In results 12 weeks combined hypolipidemic therapy with «Ateroblock» and «Aktalipid» in patients with metabolic syndrome - diabetes mellitus type 2 with arterial hypertension and ischemic heart disease were obtained 6 % decrement HbА1с, efficiency 20 % decrement absolute cardiovascular risk, direct correlation between blood viscosity and high cardiovascular risk, negative correlation between blood viscosity and level glycemia, HbA1c. Different set of separate and combined effectiveness of the use of drugs «Aktalipid» and «Ateroblok» in adjusting for blood viscosity low and medium shear rates in patients with metabolic syndrome - type 2 diabetes with hypertension and coronary heart disease. A significant correlation between the rheological parameters of blood glycated hemoglobin, the source and target glycemia. Half of the group of patients receiving combination therapy «Ateroblokom» and «Aktalipidom» found significant reduction in the absolute, relative risk of cardiovascular events by improving the rheological parameters of blood «macrovascular» shear rate.
Pages: 57-65
References
  1. Plehn J.F., Davis B.R., Frank M., Sacks F.M., Rouleau J.L, Preffer M.A., Bemstein V, Cuddy E., Moye L.A., Piller L.B., Rutherford J., Simpson L.M., Braunwald E. Reduction of Stroke Incidence After Myocardial Infarction With Pravastating: The Cholesterol and Recurrent Events (CARE) Study // Circulation. 1999. V. 99. P. 216-223.
  2. Downs J.R., Clearfield M., Weis S., Tyroler H.A., Whitney E.J., Kruyer W., Laugendorfer A., Shapiro D.R., Beer P.A., Stein A., Goto A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS // JAMA. 1998. V. 279. P.1615-1622.
  3. Schwarts G.G., Olson A.G., Ezekowitz M.D., Gans P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., Stern T. For the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigatotors. Effects of Atorvastatin on early recurrent Ischemic Events in acute Coronary Syndromes // JAMA. 2001. V. 285. P. 1711-1718.
  4. The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes // N. Engl. J. Med. 2011. V. 364. P. 818-828.
  5. Петина M.М., Гороховская Г.Н., Давыдов А.Л. Особенности реологических свойств крови у больных сахарным диабетом 2 типа с клиническими проявлениями ишемической болезни сердца // Сб. мат. VII Росс. нац. конгресса «Человек и лекарство». Москва. 2010. С. 215.
  6. Древаль А.В. Лечение сахарного диабета и сопутствующих заболеваний. М.: Эксмо. 2010. 352 с.
  7. Минушкина Л.О. Возможности применения симвастатина в клинической практике // Фарматека. 2008. Т. 20. С. 17 - 20.
  8. Заславская Р.М., Тулемисов Е.У., Смирнова Л.В., Айтмагамбетова Б.А. Сосудистые осложнения у больных сахарным диабетом. Альтернативные методы диагностики и лечения. М.: МЕДПРАКТИКА-М. 2006. 220 с.
  9. Соболевская Н.В., Спасов А.А., Петраевский А.А. ,Апухтин А.Ф., Стаценко М.Е. Оптимизация терапии микроангиопатий у больных сахарным диабетом второго типа с применением дипиридамола // Вестник ВолГМУ. 2005. № 4(16). С. 35-37.
  10. Stene L., Joner G. Norwegion Childhood Diabetes Study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population based, case-control study // Am. J. Clin. Nutr. 2003. V. 78(6). P. 1128-1134.
  11. Desci T., Szabo E., Kozari A., Erhardt E., Marosvolgyi T., Solvesz G. Polyunsaturated fatty acids in plasma lipids of diabetic children during and after diabetic ketoacidosis // Acta. Paediatr. 2005. V. 94(7). P. 850-855.
  12. MacLean C.H. ,Mojica W.A., Morton S.C., Pencharz J., Hasenfeld Garland R., Tu W., Newberry S.J., Jungvig L.K., Grossman J., Khanna P., Rhodes S., Shekelle P. Effects of ω-3 fatty acids on lipids and glycemic control in type II diabetes and metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis // Evid. Rep. Technol. Assess. (Summ). 2004. V. 89. P. 1-4.
  13. Rodrigers Y.,Christophe A.B. Long-chain ω-6 polyunsaturated fatty acids in erythrocyte phospholipids are associated with insulin resistance in nonobese type 2 diabetics // Clin. Chim. Acta. 2005. Epub 2005. Jan 11. P. 3541-3542: 195-199.
  14. Апухтин А.Ф., Инина Л.И. Влияние сочетанного применения атероблока и акталипида на липидно-реологические показатели крови у больных сахарным диабетом 2 типа // ЭНИ Забайкальский медицинский вестник. 2011. № 1. С.71-78.
  15. Александров А.А.Кардиальные свойства саха-
    роснижающих препаратов. Сульфаниламиды и сердце // Сердце. 2004. Т. 3. № 1. С. 34-35.
  16. Патент №2402325 от (РФ). Способ лечения нейрососудистых осложнений сахарного диабета / М.Е. Стаценко, А.Ф. Апухтин, Л.В. Полетаева.
  17. Шилов А.М., Авшалумов А.С., Синицина Е.М., Марковский В.Б., Полещук О.И.Изменения реологических свойств крови у больных с метаболическим синдромом // Русский медицинский журнал. URL источник: http://www.cybermed.ru /articles/ detail.php-ID=8278&print=Y.
  18. Галенок В.А., Бондарь П.Н., Диккер В.Е., Ромашкин С.В. Гликолизированный гемоглобин в генезе гипоксии тканей при различных типах нарушений углеводного обмена // Гликолизированные протеины. Новосибирск: Наука. Сибирское отделение. 1989. С. 116-149.
  19. Василенко В.Х., Фельдман С.Б., Хитров Н.К. Микардиодистрофия. М.: Медицина. 1989. 272 с.
  20. Opie L.H. Miocardial energy metabolism // Adv. Cardiol., 1974. V. 12. P. 70-83.
  21. Дзизинский В.П., Казначеев А.А. Клиническая патология транскапиллярного обмена. М.: Медицина. 1975. 240с.